Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report.

Abstract:

RATIONALE:Reactivation of hepatitis B virus (HBV) after treatment with bortezomib-based regimens in HBV-positive patients with multiple myeloma (MM) has been reported in the past few years. Nevertheless, there is evidence of inhibition of HBV replication by bortezomib in transgenic mice. However, there is still no clinical evidence that bortezomib inhibits HBV. PATIENT CONCERNS:A 55-year-old MM patient with a family history of MM, who was also a chronic HBV carrier, achieved HBV clearance after treatment with a bortezomib-based regimen in combination with anti-HBV drugs. DIAGNOSES:The diagnosis was MM with chronic carrier of HBV. INTERVENTIONS:He received bortezomib-based regimen for MM as well as entecavir as a prophylaxis to prevent HBV reactivation. OUTCOMES:This patient achieved HBsAg and HBV-DNA clearance after 2 months and the remission was maintained during the next 2 years. He also achieved complete remission of MM and underwent consolidation therapy with autologous hematopoietic stem cell transplantation. LESSONS:This is the first case of MM with HBV clearance after receiving a bortezomib-based regimen combined with anti-HBV drug. Research on related mechanisms might provide new suggestions and hope for better management of HBV positive patients with MM and for the treatment of HBV patients.

journal_name

Medicine (Baltimore)

journal_title

Medicine

authors

Zhang X,Liang Y,Li X,Wang W,Tong J,Xu Y

doi

10.1097/MD.0000000000022642

subject

Has Abstract

pub_date

2020-10-02 00:00:00

pages

e22642

issue

40

eissn

0025-7974

issn

1536-5964

pii

00005792-202010020-00112

journal_volume

99

pub_type

杂志文章

相关文献

MEDICINE文献大全